antipyrine has been researched along with Brain Ischemia in 118 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients." | 9.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| "Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)." | 9.16 | Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012) |
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 9.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |
| "To assess the efficacy and safety of edaravone for acute ischaemic stroke." | 8.87 | Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011) |
| "Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually." | 8.86 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010) |
| " Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired." | 8.31 | Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 7.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset." | 7.85 | Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 7.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone." | 7.79 | Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013) |
| "A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event." | 7.79 | Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013) |
| "To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells." | 7.76 | [A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010) |
| "Our data demonstrate that isoflurane pretreatment improved rCBF and increased the regional O(2) supply and consumption in the focal ischemic area but did not affect capillary permeability during the early stage of focal cerebral ischemia." | 7.76 | The effects of isoflurane pretreatment on cerebral blood flow, capillary permeability, and oxygen consumption in focal cerebral ischemia in rats. ( Chi, OZ; Hunter, C; Liu, X; Weiss, HR, 2010) |
| " Edaravone, a free radical scavenger, has neuroprotective effects against focal cerebral ischemia even in humans." | 7.75 | Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. ( Inada, T; Jomura, S; Kubo, K; Miyamoto, E; Nakao, S; Sakamoto, S; Shingu, K; Tomimoto, H; Xu, Y, 2009) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 7.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "Edaravone has been used in patients with acute ischemic stroke in Japan for over 10 years but does not have marketing authorization in Europe or America." | 6.50 | Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 5.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| "An optimal treatment for stroke in children has not been established, and this case highlights the urgent need to examine the safety and efficacy of IV t-PA and edaravone therapy for ischemic stroke in children." | 5.38 | Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012) |
| "Permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO)." | 5.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "To test the hypothesis that edaravone reduces functional dependence in ischemic stroke patients." | 5.22 | Edaravone for acute ischemic stroke - Systematic review with meta-analysis. ( Afreixo, V; Fidalgo, M; Gregório, H; Gregório, T; Magalhães, P; Ricardo Pires, J; Viseu, I, 2022) |
| "To identify prognostic factors affecting outcomes at 90 days after stroke from the viewpoint of recovery patterns, we enrolled 660 patients from the Edaravone and Argatroban Stroke Therapy for Acute Ischemic Stroke study database." | 5.17 | Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset. ( Kumagai, N; Nagao, T; Okuhara, Y; Origasa, H; Takekawa, H; Yamaguchi, T, 2013) |
| "Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS)." | 5.16 | Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS). ( Bansal, KK; Goel, D; Mitta, M; Puri, P, 2012) |
| "Edaravone treatment for up to 14 days suppresses the progression of disuse muscle atrophy and improves leg locomotor function to a greater extent than shorter-term treatment in acute stroke patients." | 5.14 | Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study. ( Higashi, Y; Kondo, H; Metoki, N; Moriwaki, H; Naritomi, H; Nishimura, H; Oda, T; Oe, H; Saito, K; Tanahashi, N; Tanaka, K; Terayama, Y; Yamamoto, Y; Yuasa, H, 2010) |
| "To assess the efficacy and safety of edaravone for acute ischaemic stroke." | 4.87 | Edaravone for acute ischaemic stroke. ( Feng, S; Li, J; Li, W; Liu, M; Wu, B; Yang, Q; Yuan, W; Zhang, S, 2011) |
| "Edaravone may be a useful neuroprotective agent to treat the > 15 million victims worldwide who are devastated by stroke annually." | 4.86 | A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? ( Lapchak, PA, 2010) |
| " Four compounds with free radical scavenging activity (tirilazad, ebselen, edaravone) or free radical trapping properties (NXY-059) have been examined in experimental models of stroke and evaluated clinically as neuroprotective agents." | 4.82 | Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers. ( Ashwood, T; Green, AR, 2005) |
| " Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a clinically approved cerebroprotective agent against ischemic stroke and amyotrophic lateral sclerosis, while new formulations that enable improvement of its physicochemical properties and biodistribution are desired." | 4.31 | Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury. ( Fukuta, T; Ikeda-Imafuku, M; Iwao, Y, 2023) |
| "Among patients treated with edaravone alone and edaravone + tPA, the mean reduction in the National Institutes of Health Stroke Scale from baseline to 3 months after the onset was 2." | 3.88 | Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes. ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2018) |
| "Edaravone is widely used to treat acute ischemic stroke (AIS) within 24 hours of onset." | 3.85 | Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5). ( Awano, H; Matsuda, H; Tanahashi, N; Yamaguchi, T, 2017) |
| "Compound IMM-H004 (7-hydroxy-5-methoxy-4-methyl-3-[4-methylpiperazin-1-yl]-2H-chromen-2-one) is a new synthetic derivative of coumarin, and previous studies showed that it exhibited antioxidant and neuroprotective roles in focal cerebral ischemia." | 3.81 | Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia. ( Chen, NH; Han, N; Zhang, W; Zuo, W, 2015) |
| "To investigate the protective effect of edaravone and danshensu conjugate (IM-009) on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanisms." | 3.81 | [Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury in rats and its underlying mechanism]. ( Chen, H; Hou, S; Zhang, S, 2015) |
| "Seventeen pediatric patients with cerebral ischemia were administered edaravone at a dose based on body weight from the standard dose given to adults." | 3.81 | Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone. ( Aihara, Y; Kawamata, T; Nakamoto, H; Okada, Y; Yamaguchi, K, 2015) |
| "One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (<80 years of age [younger group] and >80 years of age [older group]) and by treatment with or without edaravone." | 3.79 | Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. ( Abe, K; Deguchi, K; Ikeda, Y; Inoue, S; Kashihara, K; Kawada, S; Kiriyama, H; Kono, S; Kurata, T; Manabe, Y; Morimoto, N; Narai, H; Takao, Y; Takehisa, Y; Yamashita, T, 2013) |
| "A free radical scavenger, edaravone, which has been used for the treatment of ischemic stroke, was reported to cause acute kidney injury (AKI) as a fatal adverse event." | 3.79 | Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry. ( Hayashi, K; Kamouchi, M; Kitazono, T; Kiyohara, Y; Minematsu, K; Sakai, H, 2013) |
| "To compare the protective effect of nerve growth factor (NGF) and edaravone (a free radical scavenger) pretreatment against cerebral ischemia/reperfusion (I/R) injury to nerve cells." | 3.76 | [A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury]. ( Fu, JQ; Liu, H; Wang, DF, 2010) |
| "Our data demonstrate that isoflurane pretreatment improved rCBF and increased the regional O(2) supply and consumption in the focal ischemic area but did not affect capillary permeability during the early stage of focal cerebral ischemia." | 3.76 | The effects of isoflurane pretreatment on cerebral blood flow, capillary permeability, and oxygen consumption in focal cerebral ischemia in rats. ( Chi, OZ; Hunter, C; Liu, X; Weiss, HR, 2010) |
| " Edaravone, a free radical scavenger, has neuroprotective effects against focal cerebral ischemia even in humans." | 3.75 | Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats. ( Inada, T; Jomura, S; Kubo, K; Miyamoto, E; Nakao, S; Sakamoto, S; Shingu, K; Tomimoto, H; Xu, Y, 2009) |
| "Edaravone, a drug for treating acute ischemic stroke, has been reported to provoke acute renal disorders." | 3.75 | Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone. ( Hishida, A, 2009) |
| "We demonstrate that edaravone inhibits rtPA-induced cerebral hemorrhage in the ischemic brain of rats via the inhibition of MMP-9 expression in vivo, which is substantiated by inhibition of MMP-9 expression and NF-kappaB activation in HBECs." | 3.75 | Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. ( Kinouchi, T; Kitazato, KT; Nagahiro, S; Shimada, K; Tada, Y; Uno, M; Yagi, K, 2009) |
| "We investigated whether or not a combination of the selective thrombin inhibitor, argatroban, and the free radical scavenger, edaravone (MCI-186), ameliorates postischemic hypoperfusion and decreases mortality after 15 min of forebrain ischemia in the gerbil." | 3.71 | Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. ( Jin, YJ; Mima, T; Park, KC; Raicu, V; Shimizu, K, 2002) |
| "A previous study indicated that diaspirin-crosslinked hemoglobin (DCLHb) decreases cerebral ischemia after subarachnoid hemorrhage." | 3.70 | Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion. ( Cole, DJ; Cross, LM; Drummond, JC; McKay, LD; Patel, PM, 1998) |
| " The extent of cerebral ischemia during BCO was evaluated with [14C]iodoantipyrine autoradiography." | 3.69 | Resistance to cerebral ischemia in developing gerbils. ( Arai, H; Kusumoto, M; Mori, K; Sato, K, 1995) |
| "Edaravone has been used in patients with acute ischemic stroke in Japan for over 10 years but does not have marketing authorization in Europe or America." | 2.50 | Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. ( Egan, K; Macleod, M; Mead, G; Sena, E; Wu, S, 2014) |
| "Rat transient middle cerebral artery occlusion (MCAO) model was established." | 1.43 | Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model. ( Chen, J; Ding, WS; Ding, XS; Liu, XF; Shen, HC; Shen, LH; Sheng, YF; Ye, M, 2016) |
| "The results suggest that Edaravone and Scutellarin effectively suppressed the inflammatory responses in activated microglia, with Scutellarin being more efficacious within the dosage range used." | 1.40 | Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. ( Ling, EA; Rangarajan, P; Wu, C; Yuan, Y; Zha, H, 2014) |
| "Edaravone is a free radical scavenger, and borneol has shown anti-inflammatory effect." | 1.40 | The synergetic effect of edaravone and borneol in the rat model of ischemic stroke. ( Gao, LY; Hua, Y; Liao, GY; Luo, CX; Sun, WX; Tang, Y; Wu, HY; Yang, SB; Zhang, ZP; Zhou, QG; Zhu, DY, 2014) |
| "An optimal treatment for stroke in children has not been established, and this case highlights the urgent need to examine the safety and efficacy of IV t-PA and edaravone therapy for ischemic stroke in children." | 1.38 | Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger. ( Baba, H; Hashizume, M; Kuwashiro, T; Lee, S; Nagata, H; Nanishi, E; Sugimori, H, 2012) |
| "Edaravone treatment significantly reduced the lesion volume and improved the neurological score." | 1.35 | Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model. ( Fujii, M; Fujisawa, H; Gondo, T; Izuma, H; Kajiwara, K; Kato, S; Nomura, S; Oka, F; Suzuki, M; Uozumi, K, 2009) |
| "Cerebral ischemia was induced in rats by injecting 150 mug of sodium laurate into the left internal carotid artery on day 1." | 1.35 | Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. ( Asano, T; Hitomi, A; Ikegaki, I; Satoh, S; Seto, M; Toshima, Y, 2008) |
| "Treatment with serofendic acid (1-30 nmol) reduced the infarct volume in a dose-dependent manner." | 1.35 | Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats. ( Akaike, A; Katsuki, H; Kume, T; Nakamura, T; Niidome, T; Sugimoto, H, 2008) |
| "In in vitro models of cerebral ischemia, exposure to hydrogen peroxide or glutamate induced cell death with overactivation of PARP, and treatment with DR2313 reduced excessive formation of poly(ADP-ribose) and cell death." | 1.33 | A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. ( Hasegawa, T; Ishikawa, M; Kakui, N; Nakajima, H; Ohkuma, K, 2005) |
| "Edaravone-treated animals showed significantly improved neurological outcome." | 1.33 | Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. ( Amemiya, S; Inaba, T; Kamiya, T; Katayama, Y; Kato, K; Nito, C; Shimazaki, K; Ueda, M, 2005) |
| "Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion." | 1.33 | Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005) |
| "Edaravone was administered intraperitoneally (9 mg/kg) after hypoxic-ischemic insult every 24 hours for 2, 5, or 10 consecutive days." | 1.33 | Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. ( Aoo, N; Egashira, N; Fujiwara, M; Ikeda, T; Ikenoue, T; Iwasaki, K; Mishima, K; Noor, JI; Ohta, S, 2005) |
| "Permanent focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO)." | 1.33 | Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. ( Chen, Z; Chu, LS; Mei, RH; Wei, EQ; Xu, HM; Yu, GL; Zhang, Q; Zhang, SH; Zhang, WP; Zhao, MH, 2005) |
| "Two hours after cerebral ischemia was produced in eight rats via permanent occlusion of one middle cerebral artery (MCA) with an intraluminal suture, MRI-CBF was measured over a 2." | 1.32 | Direct comparison of local cerebral blood flow rates measured by MRI arterial spin-tagging and quantitative autoradiography in a rat model of experimental cerebral ischemia. ( Brusca, T; Divine, GW; Ewing, JR; Fenstermacher, JD; Knight, RA; Nagaraja, TN; Pawa, S; Wei, L, 2003) |
| "Edaravone+tPA-treated group: Edaravone (3 mg/kg, i." | 1.32 | Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. ( Abe, K; Hayashi, T; Horiuchi, S; Kato, S; Nagano, I; Omori, N; Sato, K; Zhang, W, 2004) |
| "Edaravone and ONO-1078 were added into the incubation medium to observe their neuroprotective effects." | 1.32 | [An improved quantitative method for evaluation of ischemic injury and neuroprotection in mouse brain slices]. ( Ge, QF; Peng, GP; Wei, EQ; Yu, LF, 2003) |
| "Cerebral infarct volume and cerebral edema were measured by high-contrast silver infarct staining (SIS)." | 1.31 | Early effects of acid-base management during hypothermia on cerebral infarct volume, edema, and cerebral blood flow in acute focal cerebral ischemia in rats. ( Frietsch, T; Georgiadis, D; Kollmar, R; Kuschinsky, W; Schäbitz, WR; Schwab, S; Waschke, KF, 2002) |
| "Metabolic disruption resulted from cerebral ischemia and post-ischemia reperfusion injury was studied using proton magnetic resonance spectroscopy (1H MRS)." | 1.30 | [In vitro evaluation of metabolic change in forebrain ischemia model of rat using proton magnetic resonance spectroscopy]. ( Tanaka, N, 1997) |
| "Transient focal cerebral ischemia was produced in Sprague-Dawley rats by occluding both carotid arteries and one middle cerebral artery for 3 hours, followed by reperfusion." | 1.30 | Differential hydroxylation of salicylate in core and penumbra regions during focal reversible cerebral ischemia. ( Bennett, JP; Kassell, NF; Kwan, AL; Lee, KS; Solenski, NJ; Yanamoto, H, 1997) |
| "For focal cerebral ischemia induction, two threads were flushed upward simultaneously into the internal carotid artery, resulting in a flow reduction in the ipsilateral MCA." | 1.30 | Comparison of transcranial Doppler flow velocity and cerebral blood flow during focal ischemia in rabbits. ( Daffertshofer, M; Els, T; Hennerici, M; Kuschinsky, W; Schroeck, H, 1999) |
| "During cerebral hypoxia-ischemia (unilateral common carotid artery ligation and hypoxia with 8% oxygen), blood flows to all regions of the ipsilateral cerebral hemisphere were not different from control at 10 and 20 min." | 1.28 | Regional cerebral blood flow during hypoxia-ischemia in the immature rat: comparison of iodoantipyrine and iodoamphetamine as radioactive tracers. ( Bryan, RM; Ringel, M; Vannucci, RC, 1991) |
| "Forebrain ischemia was induced in Mongolian gerbils by bilateral occlusion of the common carotid arteries for 30 minutes." | 1.28 | Parallel changes in brain tissue blood flow and mitochondrial function during and after 30 minutes of bilateral forebrain ischemia in the gerbil. ( Kovách, AG; Mela-Riker, L; Nádasy, GL; Reivich, M, 1989) |
| "Experimental studies of embolic cerebral ischemia using the rat are limited by variability in the location, size, and frequency of lesions produced." | 1.27 | A model of embolic cerebral ischemia in the rat. ( Penar, PL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (9.32) | 18.7374 |
| 1990's | 24 (20.34) | 18.2507 |
| 2000's | 44 (37.29) | 29.6817 |
| 2010's | 36 (30.51) | 24.3611 |
| 2020's | 3 (2.54) | 2.80 |
| Authors | Studies |
|---|---|
| Fidalgo, M | 1 |
| Ricardo Pires, J | 1 |
| Viseu, I | 1 |
| Magalhães, P | 1 |
| Gregório, H | 1 |
| Afreixo, V | 1 |
| Gregório, T | 1 |
| Fukuta, T | 1 |
| Ikeda-Imafuku, M | 1 |
| Iwao, Y | 1 |
| Shi, X | 1 |
| Ohta, Y | 2 |
| Nakano, Y | 1 |
| Liu, X | 4 |
| Tadokoro, K | 1 |
| Feng, T | 1 |
| Nomura, E | 1 |
| Tsunoda, K | 1 |
| Sasaki, R | 1 |
| Matsumoto, N | 1 |
| Osakada, Y | 1 |
| Bian, Y | 1 |
| Bian, Z | 1 |
| Omote, Y | 3 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 5 |
| Abe, K | 6 |
| Jin, Q | 1 |
| Cai, Y | 1 |
| Li, S | 1 |
| Liu, H | 4 |
| Zhou, X | 1 |
| Lu, C | 1 |
| Gao, X | 1 |
| Qian, J | 1 |
| Zhang, J | 2 |
| Ju, S | 1 |
| Li, C | 1 |
| Zhang, D | 1 |
| Xiao, Y | 1 |
| Lv, P | 1 |
| Teng, Z | 1 |
| Dong, Y | 1 |
| Qi, Q | 1 |
| Liu, Z | 1 |
| Takase, H | 1 |
| Liang, AC | 1 |
| Miyamoto, N | 3 |
| Hamanaka, G | 1 |
| Ohtomo, R | 1 |
| Maki, T | 2 |
| Pham, LD | 2 |
| Lok, J | 1 |
| Lo, EH | 2 |
| Arai, K | 2 |
| Tanahashi, N | 4 |
| Yamaguchi, T | 4 |
| Awano, H | 2 |
| Matsuda, H | 2 |
| Povlsen, GK | 1 |
| Johansson, SE | 1 |
| Larsen, CC | 1 |
| Samraj, AK | 1 |
| Edvinsson, L | 1 |
| Kono, S | 2 |
| Deguchi, K | 4 |
| Morimoto, N | 1 |
| Kurata, T | 1 |
| Ikeda, Y | 2 |
| Narai, H | 1 |
| Manabe, Y | 1 |
| Takao, Y | 1 |
| Kawada, S | 1 |
| Kashihara, K | 1 |
| Takehisa, Y | 1 |
| Inoue, S | 1 |
| Kiriyama, H | 1 |
| Wang, G | 2 |
| Su, J | 1 |
| Li, L | 1 |
| Feng, J | 1 |
| Shi, L | 1 |
| He, W | 1 |
| Liu, Y | 1 |
| Wu, CY | 1 |
| Zha, H | 2 |
| Xia, QQ | 1 |
| Yuan, Y | 2 |
| Liang, XY | 1 |
| Li, JH | 1 |
| Guo, ZY | 1 |
| Li, JJ | 1 |
| Mitta, M | 1 |
| Goel, D | 1 |
| Bansal, KK | 1 |
| Puri, P | 1 |
| Kamouchi, M | 1 |
| Sakai, H | 1 |
| Kiyohara, Y | 1 |
| Minematsu, K | 1 |
| Hayashi, K | 1 |
| Kitazono, T | 1 |
| Tian, F | 1 |
| Kawai, H | 2 |
| Hayakawa, K | 1 |
| Seo, JH | 1 |
| Mandeville, ET | 1 |
| Mandeville, JB | 1 |
| Kim, KW | 1 |
| Wu, S | 1 |
| Sena, E | 1 |
| Egan, K | 1 |
| Macleod, M | 1 |
| Mead, G | 1 |
| Connell, BJ | 1 |
| Saleh, MC | 1 |
| Kucukkaya, I | 1 |
| Abd-El-Aziz, AS | 1 |
| Khan, BV | 1 |
| Saleh, TM | 2 |
| Liu, N | 1 |
| Liu, W | 1 |
| Yunoki, T | 1 |
| Deguchi, S | 1 |
| Wu, HY | 1 |
| Tang, Y | 1 |
| Gao, LY | 1 |
| Sun, WX | 1 |
| Hua, Y | 1 |
| Yang, SB | 1 |
| Zhang, ZP | 1 |
| Liao, GY | 1 |
| Zhou, QG | 1 |
| Luo, CX | 1 |
| Zhu, DY | 1 |
| Ren, Y | 1 |
| Wei, B | 1 |
| Song, X | 2 |
| An, N | 1 |
| Zhou, Y | 1 |
| Jin, X | 1 |
| Zhang, Y | 1 |
| Rangarajan, P | 1 |
| Ling, EA | 1 |
| Wu, C | 1 |
| Zuo, W | 1 |
| Zhang, W | 2 |
| Han, N | 1 |
| Chen, NH | 1 |
| Zhang, S | 2 |
| Hou, S | 1 |
| Chen, H | 1 |
| Nakamoto, H | 1 |
| Aihara, Y | 1 |
| Yamaguchi, K | 1 |
| Kawamata, T | 1 |
| Okada, Y | 1 |
| Chi, OZ | 3 |
| Barsoum, S | 1 |
| Vega-Cotto, NM | 1 |
| Jacinto, E | 1 |
| Mellender, SJ | 1 |
| Weiss, HR | 3 |
| Shen, LH | 1 |
| Chen, J | 1 |
| Shen, HC | 1 |
| Ye, M | 1 |
| Liu, XF | 1 |
| Ding, WS | 1 |
| Sheng, YF | 1 |
| Ding, XS | 1 |
| Engel, DC | 1 |
| Mies, G | 1 |
| Terpolilli, NA | 1 |
| Trabold, R | 1 |
| Loch, A | 1 |
| De Zeeuw, CI | 1 |
| Weber, JT | 1 |
| Maas, AI | 1 |
| Plesnila, N | 1 |
| Wang, DF | 3 |
| Fu, JQ | 2 |
| Hishida, A | 1 |
| Yagi, K | 1 |
| Kitazato, KT | 1 |
| Uno, M | 1 |
| Tada, Y | 1 |
| Kinouchi, T | 1 |
| Shimada, K | 1 |
| Nagahiro, S | 1 |
| Kamiya, T | 2 |
| Inaba, T | 2 |
| Zhang, H | 1 |
| Shang, J | 1 |
| Miyazaki, K | 1 |
| Ohtsuka, A | 1 |
| Katayama, Y | 4 |
| Oka, F | 1 |
| Fujisawa, H | 1 |
| Nomura, S | 1 |
| Kajiwara, K | 1 |
| Kato, S | 2 |
| Fujii, M | 1 |
| Izuma, H | 1 |
| Uozumi, K | 1 |
| Gondo, T | 1 |
| Suzuki, M | 1 |
| Ueno, Y | 1 |
| Zhang, N | 2 |
| Tanaka, R | 2 |
| Hattori, N | 1 |
| Urabe, T | 2 |
| Kubo, K | 1 |
| Nakao, S | 1 |
| Jomura, S | 1 |
| Sakamoto, S | 1 |
| Miyamoto, E | 1 |
| Xu, Y | 1 |
| Tomimoto, H | 1 |
| Inada, T | 1 |
| Shingu, K | 1 |
| Guo, Q | 1 |
| Namura, S | 1 |
| Kikuchi, K | 2 |
| Tancharoen, S | 1 |
| Matsuda, F | 1 |
| Biswas, KK | 1 |
| Ito, T | 1 |
| Morimoto, Y | 1 |
| Oyama, Y | 1 |
| Takenouchi, K | 1 |
| Miura, N | 1 |
| Arimura, N | 1 |
| Nawa, Y | 1 |
| Meng, X | 1 |
| Shrestha, B | 1 |
| Arimura, S | 1 |
| Iwata, M | 1 |
| Mera, K | 1 |
| Sameshima, H | 1 |
| Ohno, Y | 1 |
| Maenosono, R | 1 |
| Tajima, Y | 1 |
| Uchikado, H | 1 |
| Kuramoto, T | 1 |
| Nakayama, K | 1 |
| Shigemori, M | 1 |
| Yoshida, Y | 1 |
| Hashiguchi, T | 1 |
| Maruyama, I | 1 |
| Kawahara, K | 1 |
| Yamamoto, Y | 2 |
| Yanagisawa, M | 1 |
| Tak, NW | 1 |
| Watanabe, K | 3 |
| Takahashi, C | 1 |
| Fujisawa, A | 1 |
| Kashiba, M | 1 |
| Tanaka, M | 2 |
| Hunter, C | 2 |
| Richard, MJ | 1 |
| El Bahh, B | 1 |
| Zidichouski, JA | 1 |
| Lapchak, PA | 1 |
| Naritomi, H | 1 |
| Moriwaki, H | 1 |
| Metoki, N | 1 |
| Nishimura, H | 1 |
| Higashi, Y | 1 |
| Yuasa, H | 1 |
| Oe, H | 1 |
| Tanaka, K | 2 |
| Saito, K | 1 |
| Terayama, Y | 1 |
| Oda, T | 1 |
| Kondo, H | 1 |
| Chi, Y | 1 |
| Jiao, L | 1 |
| Li, Z | 1 |
| Chen, Y | 1 |
| Xu, S | 1 |
| Baba, H | 1 |
| Sugimori, H | 1 |
| Nanishi, E | 1 |
| Nagata, H | 1 |
| Lee, S | 1 |
| Kuwashiro, T | 1 |
| Hashizume, M | 1 |
| Feng, S | 1 |
| Yang, Q | 1 |
| Liu, M | 2 |
| Li, W | 2 |
| Yuan, W | 1 |
| Wu, B | 1 |
| Li, J | 1 |
| Yao, N | 1 |
| Liu, XL | 1 |
| Kumagai, N | 1 |
| Origasa, H | 1 |
| Nagao, T | 1 |
| Takekawa, H | 1 |
| Okuhara, Y | 1 |
| Kollmar, R | 1 |
| Frietsch, T | 1 |
| Georgiadis, D | 1 |
| Schäbitz, WR | 1 |
| Waschke, KF | 1 |
| Kuschinsky, W | 3 |
| Schwab, S | 1 |
| Otori, T | 1 |
| Greenberg, JH | 2 |
| Welsh, FA | 1 |
| Ewing, JR | 1 |
| Wei, L | 3 |
| Knight, RA | 1 |
| Pawa, S | 1 |
| Nagaraja, TN | 1 |
| Brusca, T | 1 |
| Divine, GW | 1 |
| Fenstermacher, JD | 3 |
| Ge, QF | 1 |
| Wei, EQ | 3 |
| Peng, GP | 1 |
| Yu, LF | 1 |
| McColl, BW | 1 |
| Carswell, HV | 1 |
| McCulloch, J | 7 |
| Horsburgh, K | 1 |
| Watanabe, T | 5 |
| Takamatsu, Y | 1 |
| Tobe, A | 1 |
| Wang, ML | 1 |
| Liu, LY | 1 |
| Sato, K | 2 |
| Hayashi, T | 1 |
| Omori, N | 1 |
| Nagano, I | 1 |
| Horiuchi, S | 1 |
| Igarashi, H | 2 |
| Qi, X | 1 |
| Okuma, Y | 1 |
| Hosoi, T | 1 |
| Nomura, Y | 1 |
| Yu, GL | 1 |
| Zhang, SH | 1 |
| Xu, HM | 1 |
| Chu, LS | 1 |
| Zhang, WP | 1 |
| Zhang, Q | 1 |
| Chen, Z | 1 |
| Mei, RH | 1 |
| Zhao, MH | 1 |
| Nakajima, H | 1 |
| Kakui, N | 1 |
| Ohkuma, K | 1 |
| Ishikawa, M | 1 |
| Hasegawa, T | 1 |
| Shichinohe, H | 1 |
| Kuroda, S | 1 |
| Yasuda, H | 1 |
| Ishikawa, T | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Iwasaki, Y | 1 |
| Otani, H | 1 |
| Togashi, H | 1 |
| Jesmin, S | 1 |
| Sakuma, I | 1 |
| Matsumoto, M | 1 |
| Kakehata, H | 1 |
| Yoshioka, M | 1 |
| Green, AR | 1 |
| Ashwood, T | 1 |
| Amemiya, S | 1 |
| Nito, C | 1 |
| Kato, K | 1 |
| Ueda, M | 1 |
| Shimazaki, K | 1 |
| Yokota, A | 1 |
| Nakai, A | 1 |
| Taniuchi, Y | 1 |
| Okuda, N | 1 |
| Nakai, M | 1 |
| Takeshita, T | 1 |
| Lee, JH | 1 |
| Park, SY | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Komine-Kobayashi, M | 1 |
| Mizuno, Y | 1 |
| Noor, JI | 1 |
| Ikeda, T | 1 |
| Mishima, K | 1 |
| Aoo, N | 1 |
| Ohta, S | 1 |
| Egashira, N | 1 |
| Iwasaki, K | 1 |
| Fujiwara, M | 1 |
| Ikenoue, T | 1 |
| Aizawa, H | 1 |
| Makita, Y | 1 |
| Sumitomo, K | 1 |
| Aburakawa, Y | 1 |
| Katayama, T | 1 |
| Nakatani-Enomoto, S | 1 |
| Suzuki, Y | 1 |
| Fujiwara, K | 1 |
| Enomoto, H | 1 |
| Kuroda, K | 1 |
| Kimura, T | 1 |
| Yahara, O | 1 |
| Koyama, S | 1 |
| Maruyama, J | 1 |
| Nakamura, M | 1 |
| Hasebe, N | 1 |
| Itoh, Y | 2 |
| Takaoka, R | 1 |
| Ohira, M | 1 |
| Abe, T | 1 |
| Suzuki, N | 1 |
| Kitagawa, Y | 1 |
| Inatomi, Y | 1 |
| Takita, T | 1 |
| Yonehara, T | 1 |
| Fujioka, S | 1 |
| Hashimoto, Y | 1 |
| Hirano, T | 1 |
| Uchino, M | 1 |
| Ma, M | 1 |
| Wen, J | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Suda, S | 1 |
| Arai, Y | 1 |
| Andou, J | 1 |
| Chishiki, T | 1 |
| Takizawa, S | 1 |
| Izuhara, Y | 1 |
| Kitao, Y | 1 |
| Hori, O | 1 |
| Ogawa, S | 1 |
| Morita, Y | 1 |
| Takagi, S | 1 |
| van Ypersele de Strihou, C | 1 |
| Miyata, T | 1 |
| Satoh, S | 1 |
| Toshima, Y | 1 |
| Hitomi, A | 1 |
| Ikegaki, I | 1 |
| Seto, M | 1 |
| Asano, T | 1 |
| Nakamura, T | 1 |
| Kume, T | 1 |
| Katsuki, H | 1 |
| Niidome, T | 1 |
| Sugimoto, H | 1 |
| Akaike, A | 1 |
| Tamura, A | 1 |
| Graham, DI | 5 |
| Teasdale, GM | 3 |
| Kusumoto, M | 1 |
| Arai, H | 1 |
| Mori, K | 1 |
| Frerichs, KU | 1 |
| Kennedy, C | 1 |
| Sokoloff, L | 1 |
| Hallenbeck, JM | 1 |
| Yuki, S | 3 |
| Egawa, M | 1 |
| Nishi, H | 2 |
| Araki, N | 1 |
| Karp, A | 1 |
| Mackay, KB | 1 |
| Kusumoto, K | 1 |
| Fukuuchi, Y | 1 |
| Gomi, S | 1 |
| Takashima, S | 1 |
| Mihara, B | 1 |
| Shirai, T | 1 |
| Nogawa, S | 1 |
| Nozaki, H | 1 |
| Nagata, E | 1 |
| Tsuchiya, M | 2 |
| Sako, K | 3 |
| Yura, S | 2 |
| Yonemasu, Y | 3 |
| Patel, TR | 1 |
| McAuley, MA | 1 |
| Breu, V | 1 |
| Nakai, H | 1 |
| Suga, M | 1 |
| Saito, KI | 2 |
| Tanaka, N | 1 |
| Yamamoto, T | 1 |
| Mitsuka, M | 1 |
| Kogure, K | 1 |
| Solenski, NJ | 1 |
| Kwan, AL | 1 |
| Yanamoto, H | 1 |
| Bennett, JP | 1 |
| Kassell, NF | 1 |
| Lee, KS | 1 |
| Roos, MW | 1 |
| Sperber, GO | 1 |
| Tohyama, Y | 1 |
| Mizuno, A | 1 |
| Umemura, K | 1 |
| Nakashima, M | 1 |
| Tsekos, NV | 1 |
| Zhang, F | 1 |
| Merkle, H | 1 |
| Nagayama, M | 1 |
| Iadecola, C | 1 |
| Kim, SG | 1 |
| Cole, DJ | 1 |
| McKay, LD | 1 |
| Drummond, JC | 1 |
| Patel, PM | 1 |
| Cross, LM | 1 |
| Craven, K | 1 |
| Erinjeri, J | 1 |
| Liang, GE | 1 |
| Bereczki, D | 1 |
| Rovainen, CM | 1 |
| Woolsey, TA | 1 |
| Vogel, J | 1 |
| Möbius, C | 1 |
| Els, T | 1 |
| Daffertshofer, M | 1 |
| Schroeck, H | 1 |
| Hennerici, M | 1 |
| Majid, A | 1 |
| He, YY | 1 |
| Gidday, JM | 1 |
| Kaplan, SS | 1 |
| Gonzales, ER | 1 |
| Park, TS | 1 |
| Choi, DW | 1 |
| Hsu, CY | 1 |
| Rossberg, MI | 1 |
| Murphy, SJ | 1 |
| Traystman, RJ | 1 |
| Hurn, PD | 1 |
| Zhao, W | 1 |
| Busto, R | 1 |
| Truettner, J | 1 |
| Ginsberg, MD | 1 |
| Kilic, E | 1 |
| Bähr, M | 1 |
| Hermann, DM | 1 |
| Jin, YJ | 1 |
| Mima, T | 1 |
| Raicu, V | 1 |
| Park, KC | 1 |
| Shimizu, K | 1 |
| Ringel, M | 1 |
| Bryan, RM | 1 |
| Vannucci, RC | 3 |
| Bullock, R | 1 |
| Patterson, J | 1 |
| Park, C | 1 |
| Jones, SC | 1 |
| Bose, B | 1 |
| Furlan, AJ | 1 |
| Friel, HT | 1 |
| Easley, KA | 1 |
| Meredith, MP | 1 |
| Little, JR | 1 |
| Nádasy, GL | 1 |
| Mela-Riker, L | 1 |
| Reivich, M | 1 |
| Kovách, AG | 1 |
| Dirnagl, U | 1 |
| Kaplan, B | 1 |
| Jacewicz, M | 1 |
| Pulsinelli, W | 1 |
| Kataoka, K | 1 |
| Hayakawa, T | 1 |
| Graf, R | 1 |
| Yamada, K | 1 |
| Kuroda, R | 1 |
| Abekura, M | 1 |
| Mogami, H | 1 |
| Heiss, WD | 1 |
| Oishi, R | 1 |
| Nishibori, M | 1 |
| Saeki, K | 1 |
| Lyons, DT | 2 |
| Vasta, F | 2 |
| Penar, PL | 1 |
| Mohamed, AA | 1 |
| Gotoh, O | 1 |
| Osborne, KA | 1 |
| Mendelow, AD | 1 |
| Harper, AM | 1 |
| Shigeno, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Randomized Open-Label Comparison Study on the Efficacy and Safety of Argatroban Monotherapy With Argatroban-Edaravone Combination Therapy[NCT00153946] | Phase 4 | 814 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for antipyrine and Brain Ischemia
| Article | Year |
|---|---|
Edaravone for acute ischemic stroke - Systematic review with meta-analysis.
Topics: Adult; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Intracranial Hemorrha | 2022 |
Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavenge | 2014 |
Edaravone's free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature.
Topics: Animals; Antipyrine; Brain Ischemia; Databases, Bibliographic; Edaravone; Free Radical Scavengers; H | 2015 |
A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?
Topics: Animals; Antipyrine; Brain Ischemia; Drug Evaluation, Preclinical; Edaravone; Free Radical Scavenger | 2010 |
Edaravone for acute ischaemic stroke.
Topics: Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Neuroprotective Agents; Rand | 2011 |
[Research and development of the free radical scavenger edaravone as a neuroprotectant].
Topics: Animals; Antipyrine; Brain Ischemia; Clinical Trials as Topic; Drug Design; Edaravone; Edema; Free R | 2004 |
[Advances in the diagnosis and treatment of cerebral ischemia during the acute phase].
Topics: Acute-Phase Reaction; Antipyrine; Brain Ischemia; Cerebrovascular Circulation; Drug Design; Drug The | 2003 |
Free radical trapping as a therapeutic approach to neuroprotection in stroke: experimental and clinical studies with NXY-059 and free radical scavengers.
Topics: Animals; Antioxidants; Antipyrine; Azoles; Benzenesulfonates; Brain Ischemia; Edaravone; Free Radica | 2005 |
3 trials available for antipyrine and Brain Ischemia
| Article | Year |
|---|---|
Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipyrine; Brain Ischemia; Cytidi | 2012 |
Effects of edaravone on muscle atrophy and locomotor function in patients with ischemic stroke: a randomized controlled pilot study.
Topics: Aged; Antipyrine; Brain Ischemia; Drug Administration Schedule; Edaravone; Female; Free Radical Scav | 2010 |
Prognostic significance of smoking in patients with acute ischemic stroke within 3 months of onset.
Topics: Aged; Aged, 80 and over; Antipyrine; Arginine; Brain Ischemia; Chi-Square Distribution; Disability E | 2013 |
107 other studies available for antipyrine and Brain Ischemia
| Article | Year |
|---|---|
Development of Edaravone Ionic Liquids and Their Application for the Treatment of Cerebral Ischemia/Reperfusion Injury.
Topics: Animals; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Ionic Liquids; Ischemic Str | 2023 |
Neuroprotective effect of CuATSM in mice stroke model by ameliorating oxidative stress.
Topics: Animals; Antipyrine; Brain Ischemia; Infarction, Middle Cerebral Artery; Mice; Neuroprotective Agent | 2021 |
Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability.
Topics: Animals; Antipyrine; Blood-Brain Barrier; Brain Ischemia; Cells, Cultured; Edaravone; Endothelial Ce | 2017 |
Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway.
Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Dose-Response Relationship, Drug; Edara | 2018 |
Protective effects of a radical scavenger edaravone on oligodendrocyte precursor cells against oxidative stress.
Topics: Animals; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Male; Mice; Mice, Inbred C5 | 2018 |
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Diabetes Mellitus; Disability Evaluation; Disea | 2018 |
Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhage.
Topics: Analysis of Variance; Animals; Antipyrine; Area Under Curve; Blood Pressure; Brain Ischemia; Butadie | 2013 |
Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
Topics: Adult; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Fibrinolytic Agents; | 2013 |
Edaravone alleviates hypoxia-acidosis/reoxygenation-induced neuronal injury by activating ERK1/2.
Topics: Acidosis; Animals; Antipyrine; Brain Ischemia; Brain-Derived Neurotrophic Factor; Caspase 3; Cell Hy | 2013 |
Expression of angiotensin II and its receptors in activated microglia in experimentally induced cerebral ischemia in the adult rats.
Topics: Aging; Angiotensin II; Animals; Antipyrine; Blotting, Western; Brain Ischemia; Cerebral Cortex; Edar | 2013 |
Acute kidney injury and edaravone in acute ischemic stroke: the Fukuoka Stroke Registry.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Case-Control Studies; Chi- | 2013 |
In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous bone marrow stromal cells (BMSCs) and edaravone.
Topics: Animals; Antipyrine; Bone Marrow Cells; Bone Marrow Transplantation; Brain; Brain Ischemia; Disease | 2013 |
Oxidative stress interferes with white matter renewal after prolonged cerebral hypoperfusion in mice.
Topics: Animals; Antipyrine; Brain Ischemia; Disease Models, Animal; Edaravone; Free Radical Scavengers; Mic | 2013 |
UPEI-300, a conjugate of lipoic acid and edaravone, mediates neuroprotection in ischemia/reperfusion.
Topics: Animals; Antipyrine; Brain Ischemia; Cell Hypoxia; Cells, Cultured; Drug Combinations; Male; Neocort | 2014 |
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.
Topics: Acetylglucosamine; Animals; Antipyrine; Astrocytes; Brain Ischemia; Cell Proliferation; Disease Mode | 2014 |
The synergetic effect of edaravone and borneol in the rat model of ischemic stroke.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Brain; Brain Ischemia; Camphanes; Cell Survival; Cell | 2014 |
Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia.
Topics: Animals; Anti-Inflammatory Agents; Antipyrine; Apigenin; Brain; Brain Ischemia; Cell Count; Cell Lin | 2014 |
Compound IMM-H004, a novel coumarin derivative, protects against CA1 cell loss and spatial learning impairments resulting from transient global ischemia.
Topics: Animals; Antipyrine; bcl-2-Associated X Protein; Brain Ischemia; CA1 Region, Hippocampal; Caspase 3; | 2015 |
[Protective effect of novel edaravone and danshensu conjugate on focal cerebral ischemia-reperfusion injury
in rats and its underlying mechanism].
Topics: Animals; Antipyrine; Brain Edema; Brain Ischemia; Cerebral Infarction; Edaravone; Lactates; Malondia | 2015 |
Efficacy, safety, and outcomes in 17 pediatric cases treated with the free radical scavenger edaravone.
Topics: Adolescent; Antipyrine; Brain Ischemia; Child; Child, Preschool; Edaravone; Female; Free Radical Sca | 2015 |
Effects of rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Blood Gas Analysis; Blood Pressure; Br | 2016 |
Possible Mechanism of Therapeutic Effect of 3-Methyl-1-phenyl-2-pyrazolin-5-one and Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model.
Topics: Animals; Antipyrine; Bone Marrow Cells; Brain Ischemia; Chemokine CXCL12; Disease Models, Animal; Ed | 2016 |
Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Cohort Studies; Edaravone; Female; Fibrinolytic | 2017 |
Changes of cerebral blood flow during the secondary expansion of a cortical contusion assessed by 14C-iodoantipyrine autoradiography in mice using a non-invasive protocol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Biomarkers; Brain; Br | 2008 |
[A comparison of protective effect of propofol and edaravone pretreatment against cerebral ischemia-reperfusion injury].
Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cell Survival; Cells, Cultured; Cerebral Cortex; Eda | 2008 |
Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone.
Topics: Acute Kidney Injury; Antipyrine; Brain Ischemia; Edaravone; Free Radical Scavengers; Humans; Logisti | 2009 |
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Topics: Animals; Antipyrine; Blood Pressure; Blotting, Western; Brain Ischemia; Cells, Cultured; Cerebral He | 2009 |
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
Topics: Animals; Antipyrine; Basement Membrane; Brain Ischemia; Cerebral Hemorrhage; Edaravone; Free Radical | 2009 |
Mechanistic insight into neurotoxicity of tissue plasminogen activator-induced thrombolysis products in a rat intraluminal middle cerebral artery occlusion model.
Topics: Animals; Antipyrine; Biomarkers; Brain Ischemia; Cerebrovascular Circulation; DNA Damage; Edaravone; | 2009 |
Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model.
Topics: Animals; Antipyrine; Apoptosis; Axons; Blood-Brain Barrier; Brain; Brain Ischemia; Cell Proliferatio | 2009 |
Edaravone, a free radical scavenger, mitigates both gray and white matter damages after global cerebral ischemia in rats.
Topics: Amyloid beta-Protein Precursor; Animals; Antipyrine; Axons; Brain; Brain Ischemia; Edaravone; Free R | 2009 |
Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.
Topics: Animals; Antipyrine; Arterial Occlusive Diseases; Autoradiography; Brain Ischemia; Capillaries; Cere | 2010 |
Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4.
Topics: Animals; Antipyrine; Aquaporin 4; Brain Edema; Brain Ischemia; Disease Models, Animal; Edaravone; Fr | 2009 |
Repeated edaravone treatment reduces oxidative cell damage in rat brain induced by middle cerebral artery occlusion.
Topics: Animals; Antioxidants; Antipyrine; Biomarkers; Brain; Brain Ischemia; Edaravone; Free Radical Scaven | 2009 |
The effects of isoflurane pretreatment on cerebral blood flow, capillary permeability, and oxygen consumption in focal cerebral ischemia in rats.
Topics: Aminoisobutyric Acids; Anesthetics, Inhalation; Animals; Antipyrine; Arterioles; Blood Gas Analysis; | 2010 |
[A comparative study on the protection effect of nerve growth factor and edaravone pretreatment against cerebral ischemia/reperfusion injury].
Topics: Animals; Animals, Newborn; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Disease Models, A | 2010 |
A novel method for inducing focal ischemia in vitro.
Topics: Animals; Antipyrine; Brain Ischemia; Cell Hypoxia; Cell Survival; Culture Media; Edaravone; Excitato | 2010 |
Effects of GABA(A) receptor blockade on regional cerebral blood flow and blood-brain barrier disruption in focal cerebral ischemia.
Topics: Aminoisobutyric Acids; Animals; Antipyrine; Bicuculline; Blood-Brain Barrier; Brain Ischemia; Carbon | 2011 |
Edaravone alleviates delayed neuronal death and long-dated cognitive dysfunction of hippocampus after transient focal ischemia in Wistar rat brains.
Topics: Animals; Antipyrine; Brain Ischemia; Cognition Disorders; Disease Models, Animal; Edaravone; Free Ra | 2011 |
Stroke in a child safely treated with intravenous tissue plasminogen activator and edaravone, a free radical scavenger.
Topics: Antipyrine; Brain Ischemia; Child; Disability Evaluation; Drug Therapy, Combination; Edaravone; Fema | 2012 |
[Neuroprotective effects of combined pretreatment with edaravone and propofol on neonatal rat cerebral cortical neurons with ischemia/reperfusion injury in vitro].
Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cell Survival; Cells, Cultured; Cerebral Cortex; Eda | 2012 |
Early effects of acid-base management during hypothermia on cerebral infarct volume, edema, and cerebral blood flow in acute focal cerebral ischemia in rats.
Topics: Acid-Base Equilibrium; Animals; Antipyrine; Autoradiography; Brain Edema; Brain Ischemia; Cerebral I | 2002 |
Cortical spreading depression causes a long-lasting decrease in cerebral blood flow and induces tolerance to permanent focal ischemia in rat brain.
Topics: Adaptation, Physiological; Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Cerebral Inf | 2003 |
Direct comparison of local cerebral blood flow rates measured by MRI arterial spin-tagging and quantitative autoradiography in a rat model of experimental cerebral ischemia.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Cerebrovascular Circulation; Echo-Planar Imagi | 2003 |
[An improved quantitative method for evaluation of ischemic injury and neuroprotection in mouse brain slices].
Topics: Alprostadil; Animals; Antipyrine; Brain Ischemia; Edaravone; Formazans; Male; Mice; Mice, Inbred ICR | 2003 |
Extension of cerebral hypoperfusion and ischaemic pathology beyond MCA territory after intraluminal filament occlusion in C57Bl/6J mice.
Topics: Analysis of Variance; Animals; Antipyrine; Autoradiography; Blood Pressure; Brain; Brain Ischemia; C | 2004 |
[Effects of edaravone, minocycline and ONO-1078 on oxygen/glucose deprivation-induced electrophysiological alteration in rat hippocampal slices].
Topics: Animals; Anti-Bacterial Agents; Antipyrine; Brain Ischemia; Chromones; Edaravone; Evoked Potentials; | 2004 |
Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
Topics: Aldehydes; Animals; Antipyrine; Brain Ischemia; Cell Count; Deoxyadenosines; Disease Models, Animal; | 2004 |
Edaravone protects against hypoxia/ischemia-induced endoplasmic reticulum dysfunction.
Topics: Animals; Antipyrine; Apoptosis; Brain Ischemia; Cells, Cultured; Edaravone; Endoplasmic Reticulum; F | 2004 |
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Topics: Acetates; Animals; Antipyrine; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Chromones; C | 2005 |
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Bridged Bicyclo Compounds, Heterocyclic; Cells, Cultured | 2005 |
Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia.
Topics: Animals; Antipyrine; Brain Ischemia; DNA-Binding Proteins; Edaravone; Ethidium; Free Radical Scaveng | 2004 |
Temporal effects of edaravone, a free radical scavenger, on transient ischemia-induced neuronal dysfunction in the rat hippocampus.
Topics: Animals; Antipyrine; Blotting, Western; Brain Ischemia; Edaravone; Fibroblast Growth Factor 2; Fluor | 2005 |
Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats.
Topics: Animals; Antipyrine; Apoptosis; bcl-2-Associated X Protein; Brain Edema; Brain Ischemia; Cerebral Co | 2005 |
Maternal treatment with MCI-186 does not improve delayed deterioration of cellular bioenergetic state and mitochondrial activity following transient intrauterine ischemia in the fetal rat brain.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Edaravone; Energy Metabolism; Female; Fetal Hypoxia; Fre | 2005 |
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede | 2005 |
Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Anti-Inflammatory Agents; Antioxidants; Antipyrine; | 2005 |
Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy.
Topics: Animals; Animals, Newborn; Antipyrine; Behavior, Animal; Brain; Brain Ischemia; Drug Administration | 2005 |
Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Ischemia; Edaravone; Female; Free Radical Scavengers; Fre | 2006 |
Reactive oxygen species generated by mitochondrial injury in human brain microvessel endothelial cells.
Topics: Antipyrine; Brain; Brain Ischemia; Cerebrovascular Circulation; Edaravone; Endothelium, Vascular; Fr | 2006 |
Edaravone in acute ischemic stroke.
Topics: Antipyrine; Brain Ischemia; Edaravone; Fibrinolytic Agents; Free Radical Scavengers; Tissue Plasmino | 2006 |
Efficacy of edaravone in cardioembolic stroke.
Topics: Aged; Antipyrine; Brain Ischemia; Creatinine; Edaravone; Female; Free Radical Scavengers; Humans; In | 2006 |
Effects of edaravone in heart of aged rats after cerebral ischemia-reperfusion injury.
Topics: Aging; Animals; Antipyrine; Apoptosis; Blotting, Western; Brain Ischemia; Cell Survival; Disease Mod | 2007 |
Effect of edaravone, a free radical scavenger, on ischemic cerebral edema assessed by magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Antipyrine; Brain Edema; Brain Ischemia; Edaravone; Female; Free Radical Sc | 2007 |
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Do | 2007 |
Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipyrine; Blood Flow Velocity; Brain Ische | 2008 |
Protective effect of serofendic acid on ischemic injury induced by occlusion of the middle cerebral artery in rats.
Topics: Animals; Antipyrine; Body Weight; Brain Ischemia; Cerebrovascular Circulation; Diterpenes; Dose-Resp | 2008 |
Focal cerebral ischaemia in the rat: 2. Regional cerebral blood flow determined by [14C]iodoantipyrine autoradiography following middle cerebral artery occlusion.
Topics: Animals; Antipyrine; Arterial Occlusive Diseases; Autoradiography; Brain Ischemia; Carbon Radioisoto | 1981 |
Resistance to cerebral ischemia in developing gerbils.
Topics: Aging; Animals; Antipyrine; Body Temperature; Brain; Brain Ischemia; Cell Death; Cerebrovascular Cir | 1995 |
Local cerebral blood flow during hibernation, a model of natural tolerance to "cerebral ischemia".
Topics: Adaptation, Physiological; Animals; Antipyrine; Autoradiography; Behavior, Animal; Blood Cells; Brai | 1994 |
Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions.
Topics: Alloxan; Animals; Antioxidants; Antipyrine; Brain; Brain Ischemia; Edaravone; Embolization, Therapeu | 1994 |
Correlation between 99mTc-bicisate and regional CBF measured with iodo-[14C]antipyrine in a primate focal ischemia model.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Carbon Radioisotopes; Cerebrovascular Circulation; Cyste | 1994 |
Effect of the kappa-1 opioid agonist CI-977 on ischemic brain damage and cerebral blood flow after middle cerebral artery occlusion in the rat.
Topics: Animals; Antipyrine; Autoradiography; Benzofurans; Blood Pressure; Brain; Brain Ischemia; Cerebral A | 1993 |
Reduction in second-messenger ligand binding sites after brain ischemia--autoradiographic Bmax and Kd determinations using digital image analysis.
Topics: Adenylyl Cyclases; Animals; Antipyrine; Autoradiography; Blood Pressure; Brain Ischemia; Carbon Radi | 1993 |
Local cerebral glucose utilisation following acute and chronic bilateral carotid artery ligation in Wistar rats: relation to changes in local cerebral blood flow.
Topics: Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Carbon Radioisotopes; Carotid Arteries; | 1993 |
Failure of an endothelin antagonist to modify hypoperfusion after transient global ischaemia in the rat.
Topics: Animals; Antipyrine; Autoradiography; Blood Pressure; Bosentan; Brain Ischemia; Carbon Radioisotopes | 1996 |
The effects of bosentan on cerebral blood flow and histopathology following middle cerebral artery occlusion in the rat.
Topics: Animals; Antipyrine; Arterial Occlusive Diseases; Autoradiography; Bosentan; Brain Ischemia; Carbon | 1996 |
Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Cerebral Arteries; Disease Models, Animal; Edaravone; Fr | 1997 |
[In vitro evaluation of metabolic change in forebrain ischemia model of rat using proton magnetic resonance spectroscopy].
Topics: Acetates; Animals; Antipyrine; Brain; Brain Ischemia; Choline; Edaravone; Free Radical Scavengers; L | 1997 |
Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia.
Topics: Animals; Antipyrine; Brain Ischemia; Cell Death; Edaravone; Free Radical Scavengers; Hippocampus; Hy | 1997 |
Differential hydroxylation of salicylate in core and penumbra regions during focal reversible cerebral ischemia.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Coloring Agents; Hydroxylation; Male; Osmolar Concentrat | 1997 |
Effects of microemboli on local blood flow in the rabbit brain.
Topics: Animals; Antipyrine; Autoradiography; Basal Ganglia; Brain; Brain Ischemia; Brain Stem; Carbon Radio | 1998 |
Hypothermia attenuates the activation of protein kinase C in focal ischemic rat brain: dual autoradiographic study of [3H]phorbol 12,13-dibutyrate and iodo[14C]antipyrine.
Topics: Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Carbon Radioisotopes; Cerebrovascular C | 1998 |
Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Cerebral Arteries; Constriction; Edaravone; Free Radical | 1998 |
Quantitative measurements of cerebral blood flow in rats using the FAIR technique: correlation with previous iodoantipyrine autoradiographic studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Autoradiography; Blood Gas Analysis; B | 1998 |
Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion.
Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Antipyrine; Aspirin; Blood; Blood Substitute | 1998 |
Local cerebral blood flow during the first hour following acute ligation of multiple arterioles in rat whisker barrel cortex.
Topics: Acute Disease; Anesthesia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Arterial Oc | 1998 |
Early delineation of ischemic tissue in rat brain cryosections by high-contrast staining.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Arterial Occlusive Diseases; Autoradio | 1999 |
Comparison of transcranial Doppler flow velocity and cerebral blood flow during focal ischemia in rabbits.
Topics: Animals; Antipyrine; Autoradiography; Blood Flow Velocity; Brain Ischemia; Carbon Radioisotopes; Cer | 1999 |
Differences in vulnerability to permanent focal cerebral ischemia among 3 common mouse strains.
Topics: Animals; Antipyrine; Autoradiography; Blood Gas Analysis; Brain Ischemia; Carbon; Carbon Radioisotop | 2000 |
LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Carbon Radioisotopes; Cerebral Infarction; Cer | 2000 |
Simultaneous measurement of cerebral blood flow and mRNA signals: pixel-based inter-modality correlational analysis.
Topics: Algorithms; Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Carbon Radioisotopes; Cereb | 2001 |
Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations.
Topics: Animals; Antipyrine; Autoradiography; Brain Edema; Brain Ischemia; Cerebrovascular Circulation; Colo | 2001 |
Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils.
Topics: Animals; Anticoagulants; Antipyrine; Arginine; Body Water; Brain Edema; Brain Ischemia; Cerebral Inf | 2002 |
Cerebral blood flow and histopathological changes following permanent bilateral carotid artery ligation in Wistar rats.
Topics: Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Carbon Radioisotopes; Carotid Arteries; | 1992 |
Regional cerebral blood flow during hypoxia-ischemia in the immature rat: comparison of iodoantipyrine and iodoamphetamine as radioactive tracers.
Topics: Amphetamines; Animals; Antipyrine; Autoradiography; Brain; Brain Ischemia; Cerebrovascular Circulati | 1991 |
Evaluation of 99mTc-hexamethylpropyleneamine oxime cerebral blood flow mapping after acute focal ischemia in rats.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Brain Mapping; Carbon Radioisotopes; Cerebral | 1991 |
CO2 reactivity and heterogeneity of cerebral blood flow in ischemic, border zone, and normal cortex.
Topics: Animals; Antipyrine; Brain; Brain Ischemia; Carbon Dioxide; Carbon Radioisotopes; Cerebral Arteries; | 1989 |
Parallel changes in brain tissue blood flow and mitochondrial function during and after 30 minutes of bilateral forebrain ischemia in the gerbil.
Topics: Animals; Antipyrine; Blood Flow Velocity; Brain Ischemia; Cerebral Cortex; Gerbillinae; Male; Mitoch | 1989 |
Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Carbon Radioisotopes; Cerebral Cortex; Cerebro | 1989 |
[Neurofunctional disturbances as related to cortical ischemia and white matter ischemia].
Topics: Animals; Antipyrine; Auditory Cortex; Autoradiography; Brain Ischemia; Carbon Radioisotopes; Cats; C | 1989 |
Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipyrine; Biogenic Monoamines; Brain; Brain Edema; Brain | 1989 |
Regional cerebral blood flow during hypoxia-ischemia in immature rats.
Topics: Animals; Animals, Newborn; Antipyrine; Autoradiography; Brain; Brain Ischemia; Carbon Radioisotopes; | 1988 |
A model of embolic cerebral ischemia in the rat.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Cerebral Arterial Diseases; Cerebrovascular Ci | 1987 |
Autoradiographic determination of regional cerebral blood flow in the immature rat.
Topics: Animals; Antipyrine; Autoradiography; Brain Ischemia; Cerebrovascular Circulation; Hypoxia, Brain; R | 1987 |
Effect of pretreatment with the calcium antagonist nimodipine on local cerebral blood flow and histopathology after middle cerebral artery occlusion.
Topics: Acid-Base Equilibrium; Animals; Antipyrine; Blood Glucose; Blood Pressure; Brain; Brain Ischemia; Ca | 1985 |
Recirculation model following MCA occlusion in rats. Cerebral blood flow, cerebrovascular permeability, and brain edema.
Topics: Aminoisobutyric Acids; Antipyrine; Arterial Occlusive Diseases; Autoradiography; Brain Edema; Brain | 1985 |